Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endocyte Inc (ECYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 243,709
  • Shares Outstanding, K 47,880
  • Annual Sales, $ 70 K
  • Annual Income, $ -43,890 K
  • 36-Month Beta 2.19
  • Price/Sales 3,249.07
  • Price/Cash Flow 0.00
  • Price/Book 2.24

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.14 +22.95%
on 10/25/17
5.47 -6.95%
on 11/10/17
+0.74 (+17.01%)
since 10/17/17
3-Month
1.17 +335.04%
on 08/21/17
6.55 -22.29%
on 10/03/17
+3.81 (+297.66%)
since 08/17/17
52-Week
1.17 +335.04%
on 08/21/17
6.55 -22.29%
on 10/03/17
+2.05 (+67.43%)
since 11/17/16

Most Recent Stories

More News
Endocyte to Present at the Jefferies 2017 London Healthcare Conference

Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company's management team will present at the Jefferies...

ECYT : 5.09 (+7.16%)
Cancer Immunotherapy Technology Projected to Create Further Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at a CAGR of 14.5 percent from the time period of 2016...

CLDX : 2.91 (+2.11%)
ARQL : 1.42 (+6.77%)
RGBP : 0.0900 (+21.62%)
RGBPP : 0.0600 (+33.33%)
ECYT : 5.09 (+7.16%)
CASI : 2.60 (+5.26%)
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss

Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.

AGEN : 3.70 (-0.27%)
LGND : 140.31 (-0.99%)
ECYT : 5.09 (+7.16%)
ADAP : 7.88 (-1.75%)
Endocyte Reports Third Quarter Financial Results

- Plans to Initiate Phase 3 Registration for Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte -

ECYT : 5.09 (+7.16%)
Endocyte, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 6, 2017 / Endocyte, Inc. (NASDAQ: ECYT) will be discussing their earnings results in their Q3 Earnings Call to be held on November 6, 2017 at 4:30 PM Eastern Time.

ECYT : 5.09 (+7.16%)
Will Endocyte (ECYT) Disappoint This Earnings Season?

Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.

AGEN : 3.70 (-0.27%)
CLVS : 63.21 (-5.49%)
ECYT : 5.09 (+7.16%)
ACAD : 27.86 (+0.80%)
Key FDA Approvals Paramount Catalyst for Biotech Run Heading Into November

The FDA has approved 34 drugs to date in 2017 after approving 22 novel drugs last year. Many biotech and pharma companies have dealt with the drug development process being lengthy and time-consuming along...

AKTX : 4.65 (+6.16%)
CTXR : 4.28 (+4.90%)
ADMS : 28.41 (+2.60%)
ECYT : 5.09 (+7.16%)
MNKD : 3.26 (+1.87%)
Endocyte Announces Third Quarter 2017 Earnings Conference Call

Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Monday, Nov. 6th, at 4:30 p.m. EST to discuss its third quarter financial results and provide an operational...

ECYT : 5.09 (+7.16%)
Endocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing Deal

NEW YORK, NY / ACCESSWIRE / October 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

ECYT : 5.09 (+7.16%)
Cancer Space Last Week Update: Pipeline Expansion in Focus

Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.

CTMX : 20.31 (+0.25%)
LLY : 82.89 (-0.66%)
ECYT : 5.09 (+7.16%)
SGEN : 59.79 (+0.84%)
CLSN : 2.00 (+3.09%)
AMGN : 170.00 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 5.49
1st Resistance Point 5.29
Last Price 5.09
1st Support Level 4.82
2nd Support Level 4.55

See More

52-Week High 6.55
Last Price 5.09
Fibonacci 61.8% 4.49
Fibonacci 50% 3.86
Fibonacci 38.2% 3.23
52-Week Low 1.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart